SHARE

Porton Pharma Solutions Joined The SBTi To Drive Climate Action Porton Pharma Solutions Joined The SBTi To Drive Climate Action
02.03.2024

Porton Pharma Solutions Joined The SBTi To Drive Climate Action

Porton Pharma Solutions Joined The SBTi To Drive Climate Action

Porton Pharma Solutions Ltd. is thrilled to announce its commitment to climate action by joining the Science Based Targets initiative (SBTi). By aligning our emissions reduction targets with the Paris Agreement goals on limiting global warming to 1.5°C, we aim to contribute towards creating a sustainable and low-carbon future.

By joining the SBTi, Porton commits to setting ambitious, science-based greenhouse gas (GHG) emissions reduction near term targets in line with the goals outlined in the Paris Agreement. These targets will be developed using the most up-to-date climate science available and will ensure that our emissions trajectory is consistent with the global effort to limit temperature rise below dangerous levels.

"We are excited to join the SBTi and commit to science-based targets, which remarks another milestone in Porton’s actions to mitigate climate change, " said Oliver Ju, Chairman of Porton. "By doing so, we are taking concrete actions to address climate change and contribute to the global collective effort. In 2023, we established a task force to comprehensively advance and implement our initiatives concerning climate change. We believe that businesses have a crucial role in leading the transition to a sustainable future, and we are committed to doing our part."

As part of our commitment to the SBTi, Porton will regularly measure and report our progress towards our targets, providing transparency and accountability to our stakeholders. Through this process, we will identify opportunities for innovation and efficiency, promoting sustainable practices throughout our operations and supply chain.


About SBTi

The Science Based Targets initiative (SBTi) is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF), aiming to drive ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.

SHARE

Porton Pharma Solutions Joined The SBTi To Drive Climate Action Porton Pharma Solutions Joined The SBTi To Drive Climate Action
Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details